This database contains 50 studies, archived under the term: "AD)."
Click here to filter this large number of results.
Treatment effects of therapeutic cholinesterase inhibitors on visuospatial processing in Alzheimer’s disease: A longitudinal functional MRI study
Thiyagesh, Subha N.,
Farrow, Tom F. D.,
Parks, Randolph W.,
Accosta-Mesa, Hector,
Hunter, Michael D.,
Young, Claire,
Wilkinson, lain D.,
Woodruff, Peter W. R.
Background/Aims: Visuospatial impairments are known to occur in Alzheimer’s disease (AD). We hypothesised that functional magnetic resonance imaging (fMRI) response in task-related brain regions would be impaired in patients with AD during the task and that treatment with acetyl cholinesterase inhibitors would enhance activations in brain regions concerned with this visual perceptual processing. Method: Ten […]
How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist
Sakakibara, Ryuji,
Ogata, Takeshi,
Uchiyama, Tomoyuki,
Kishi, Masahiko,
Ogawa, Emina,
Isaka, Shigeo,
Yuasa, Joji,
Yamamoto, Tatsuya,
Ito, Takashi,
Yamanishi, Tomonori,
Awa, Yusuke,
Yamaguchi, Chiharu,
Takahashi, Osamu
Although urinary incontinence inevitably occurs in advanced stages of dementia of any etiology, urinary urgency or frequency, also called an overactive bladder (OAB), occurs more commonly in dementia with Lewy bodies (DLB) and vascular dementia than it does in Alzheimer’s disease (AD). Acetylcholinesterase (AChE) inhibitors for dementia and anticholinergics for OAB have been widely used, […]
Anticholinergic drug use and risk for dementia: Target for dementia prevention
Jessen, Frank,
Kaduszkiewicz, Hanna,
Daerr, Moritz,
Bickel, Horst,
Pentzek, Michael,
Riedel-Heller, Steffi,
Wagner, Michael,
Weyerer, Siegfried,
Wiese, Birgitt,
van den Bussche, Hendrik,
Broich, Karl,
Maier, Wolfgang
An increasing number of longitudinal cohort studies have identified a risk increase for dementia by the chronic use of drugs with anticholinergic properties. The respective data from the German Study on Aging, Cognition and Dementia in Primary Care Patients (AgeCoDe) also showing risk increase (hazard ratio = 2.081) are reported here. The mechanisms by which […]
Treatment of vascular risk factors is associated with slower decline in Alzheimer disease
Background: There is growing evidence that vascular risk factors (VRF) contribute to cognitive decline. Whether their treatment can slow down the progression of Alzheimer disease (AD) remains unsettled. The aim of this observational study was to evaluate whether the treatment of VRF is associated with a slower cognitive decline in patients who have AD without […]
Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17β-estradiol versus conjugated equine estrogens
Wroolie, Tonita E.,
Kenna, Heather A.,
Williams, Katherine E.,
Powers, Bevin N.,
Holcomb, Megan,
Khaylis, Anna,
Rasgon, Natalie L.
Objective: Much controversy exists and many questions remain unanswered about the effects of hormone therapy (HT) on cognition in postmenopausal women. There is growing evidence suggesting that HT compounds containing conjugated equine estrogen (CEE) have negative effects on cognition whereas 17β-estradiol (17β-E) either has positive or neutral effects. The present study sought to further examine […]
A community-based approach to trials of aerobic exercise in aging and Alzheimer’s disease
Vidoni, Eric D.,
Van Sciver, Angela,
Johnson, David K.,
He, Jinghua,
Honea, Robyn,
Haines, Brian,
Goodwin, Jami,
Laubinger, M. Pat,
Anderson, Heather S.,
Kluding, Patricia M.,
Donnelly, Joseph E.,
Billinger, Sandra A.,
Burns, Jeffrey M.
The benefits of exercise for aging have received considerable attention in both the popular and academic press. The putative benefits of exercise for maximizing cognitive function and supporting brain health have great potential for combating Alzheimer’s disease (AD). Aerobic exercise offers a low-cost, low-risk intervention that is widely available and may have disease modifying effects. […]
Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease
Uenaka, Kazunori,
Nakano, Masako,
Willis, Brian A.,
Friedrich, Stuart,
Ferguson-Sells, Lisa,
Dean, Robert A.,
Ieiri, Ichiro,
Siemers, Eric R.
Objectives: Solanezumab is a humanized anti-amyloid β monoclonal antibody being developed as a passive immunization treatment to slow the progression of Alzheimer disease (AD). Pharmacokinetics (PK), pharmacodynamics, safety, and tolerability after a single dose of solanezumab were compared between Japanese and white patients with AD.; Methods: Japanese and white patients with mild to moderate AD […]